Skip to Main Content

Paper Details

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Leukemia
44
2018
AML, AML cells, AML progenitors, AML xenograft model, FLT3, IRAK1, IRAK1 kinase domain, Interleukin-1 receptor-associated kinase 1, JAK1, JAK2, Pacritinib, acute, acute myeloid leukemia, interleukin-1 receptor-associated kinase-1, leukemia, leukemic, leukemic cells, multiple cancers, pacritinib, primary AML, primary AML samples, quizartinib, ruxolitinib, xenograft model
Author NameAffiliation
Stephen E KurtzKnight Cancer Institute, Oregon Health & Science University
Shawn MahmoodKnight Cancer Institute, Oregon Health & Science University
Monika A DavareOregon Health & Science University
Monika A DavareOregon Health & Science University
Andy KaempfKnight Cancer Institute, Oregon Health & Science University
Jason E McDermottPacific Northwest National Laboratory
Jason E McDermottPacific Northwest National Laboratory
Tao LiuPacific Northwest National Laboratory
Tao LiuPacific Northwest National Laboratory
Samuel H PaynePacific Northwest National Laboratory
Samuel H PaynePacific Northwest National Laboratory
Ujwal ShindeOregon Health & Science University
Karin D RodlandPacific Northwest National Laboratory
Karin D RodlandPacific Northwest National Laboratory
Motomi MoriKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerHoward Hughes Medical Institute
Anupriya AgarwalKnight Cancer Institute, Oregon Health & Science University
Anupriya AgarwalOregon Health & Science University
  • 1 - 19

Datasets

Release 1.2